| Component: (Network and Table) | |
|---|---|
| Network | 2423402 - Disclosure - Other - Net, Expense (Income) (Details) (http://www.lilly.com/role/OtherNetExpenseIncomeDetails) |
| Table | Statement [Table] |
| Reporting Entity [Axis] | 0000059478 (http://www.sec.gov/CIK) |
| Products and Services [Axis] | Products and Services [Domain] |
| Statement [Line Items] | Period [Axis] | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
2016-10-01 - 2016-12-31 | 2016-07-01 - 2016-09-30 | 2016-04-01 - 2016-06-30 | 2016-01-01 - 2016-12-31 | 2016-01-01 - 2016-03-31 | 2015-10-01 - 2015-12-31 | 2015-07-01 - 2015-09-30 | 2015-04-01 - 2015-06-30 | 2015-01-01 - 2015-12-31 | 2015-01-01 - 2015-03-31 | 2014-01-01 - 2014-12-31 | |
Other Revenue, Net | 833,700,000 | 808,100,000 | 788,400,000 | ||||||||
Income related to termination of the exenatide collaboration with Amylin | |||||||||||
Interest Expense | 185,200,000 | 161,200,000 | 148,800,000 | ||||||||
Investment Income, Interest | ( | ( | ( | ||||||||
Gains (Losses) on Extinguishment of Debt | 0 | 166,700,000 | 0 | ||||||||
Other (income)expense | (195,600,000) | (341,500,000) | (368,300,000) | ||||||||
Nonoperating Income (Expense), Total | (15,800,000) | (27,200,000) | (21,200,000) | 84,800,000 | 149,000,000 | (44,700,000) | (86,500,000) | 123,300,000 | (100,600,000) | (92,700,000) | (340,500,000) |